NCT04869501No Longer Available不适用
Expanded Access Protocol for an Intermediate Size Population-use of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 3
研究概览
简要总结
This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participation in the Tracon sponsored 4309ST101 or I-Mab sponsored TJ004309STM103 study and thought to have potential to derive clinical benefit from continued treatment in the opinion of the parent study investigator from dosing of TJ004309 in combination with atezolizumab.
- •Willing or able to comply with study treatment and standard of care testing and procedures.
排除标准
- •Any unresolved ongoing toxicity or clinical event that would make continued treatment with TJ004309 inappropriate.
- •Current treatment in another clinical study or treatment with other standard of care therapy.
- •Currently pregnant.
- •Current evidence of any condition (including medical, psychiatric or substance abuse disorder), therapy, or laboratory abnormality that might interfere with the patient's participation or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
研究者
研究点 (3)
Loading locations...
相似试验
No Longer Available
不适用
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 InfectionModerate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19NCT04366830Mesoblast International Sàrl
Unknown
不适用
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)NCT04456439Mesoblast International Sàrl
Approved For Marketing
不适用
An Intermediate Size Expanded Access Protocol of AMX0035 for ALSAmyotrophic Lateral SclerosisNCT05286372Amylyx Pharmaceuticals Inc.
Available
不适用
Expanded Access to Ensartinib for Participants With ALK+ NSCLCALK Gene Rearrangement PositiveNon-Small Cell Lung CancerNCT04146571Xcovery Holdings, Inc.
Available
不适用
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Spinocerebellar AtaxiasSCANCT06034886Biohaven Pharmaceuticals, Inc.